2024

• JW-2286 IND approval for Phase 1
• ‘Development of the Candidate for Standard Treatment-Resistant/Refractory Prostate Cancer through Direct Inhibition of XBP1s, a Mediator of ER stress’, selected as ‘2024 Korea Drug Development Fund’

2023

• URC-102 phase 3b, JW-1601 phase 2b
• Signed Memorandum of Understanding (MOU) with MBD to develop
  innovative anti-cancer drugs using the 3D cancer organoid platform
• ‘Discovery of STAT5/STAT3 Selective Inhibitor for AML, in case of
  Non-responses or Resistance to FLT3 inhibitor’, selected as
  ‘2023 Korea Drug Development Fund’

2021

• Completed phase 2b of gout treatment
• ‘The generation of candidate for atopic dermatitis via selective
  STAT3 inhibition’, selected as ‘2021 Korea Drug Development Fund’

2020

• ST-2286(JW2286)
  Target anticancer drug preclinical candidate​
  License out for JW Pharmaceutical

2019

• URC-102, Anti-Gout Drug Candidate​
  JW Pharmaceutical signs out-licensing agreement with Simcere

2018

• Collaboration research agreement on new drugs between C&C
  Research Laboratories and A^*STAR, Singapore​
• FR-1345 (JW1601) atopic dermatitis drug candidate​
  JW Pharmaceutical signs out-licensing agreement with LEO Pharma

2010

• URC-102 Anti-gout agent
  License out to JW Pharmaceutical in Korea and Chugai
  Pharmaceutical in Japan
  Entry into phase II study (2014)

2001

• Anti-breast cancer drug
  Out-Licensing of drug candidates
  
  
• Anti-IBS (Irritable Bowel Syndrome) drug
  Out-Licensing of drug candidates